Inactive Instrument

Metabolix, Inc. Stock Nasdaq

US5910188094

Biotechnology & Medical Research

Analysts' recommendations : Metabolix, Inc.

09/02/24	Lake Street Downgrades Yield10 Bioscience to Hold From Buy, Cuts Price Target to $0.50 From $3	MT
17/08/23	HC Wainwright Adjusts Price Target on Yield10 Bioscience to $4 From $25, Keeps Buy Rating	MT
04/05/22	Univest Initiates Coverage of Yield10 Bioscience With Buy Rating, $5 Price Target	MT
03/05/22	Univest Securities Starts Yield10 Bioscience at Buy With $5 Price Target	MT
22/04/22	Lake Street Initiates Yield10 Bioscience at Buy with $12 Price Target	MT

More recommendations

Press Releases : Metabolix, Inc.

13/11/24	Yield10 Bioscience : Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals; Special Meeting Adjourned to Thursday, November 14, 2024 Form 8 K	PU
15/08/24	Yield10 Bioscience Announces Second Quarter 2024 Financial Results	AQ
17/07/24	Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets	AQ
17/06/24	Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina	AQ
13/06/24	Yield10 Bioscience : Certificate of Incorporation/Bylaws Form 8 K	PU

More press releases

Managers and Directors : Metabolix, Inc.

Manager	Title	Age	Since
Oliver Peoples CEO	Chief Executive Officer	68	17/10/2016
Charles Haaser DFI	Director of Finance/CFO	70	03/11/2014

Director	Title	Age	Since
Oliver Peoples BRD	Director/Board Member	68	07/07/2009
Robert van Nostrand CHM	Chairman	69	08/11/2011
Richard Hamilton BRD	Director/Board Member	63	02/03/2017

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
METABOLIX, INC.	-2.20%	-3.85%	-	-	6.89M
LONZA GROUP AG	-2.25%	-2.26%	-1.31%	+15.20%	50.35B
REVOLUTION MEDICINES, INC.	+0.78%	-4.65%	+430.22%	+501.63%	45.2B
IQVIA HOLDINGS INC.	+2.95%	+3.52%	+47.12%	+21.08%	44.71B
BEONE MEDICINES AG	+0.25%	-2.63%	+7.86%	+73.60%	41.24B
CELLTRION, INC.	+0.43%	-2.20%	+14.55%	+49.08%	33.08B
ASCENDIS PHARMA A/S	+1.43%	+8.73%	-	-	17.81B
MEDPACE HOLDINGS, INC.	+0.06%	-2.97%	+23.31%	+116.96%	16.56B
EUROFINS SCIENTIFIC SE	-0.38%	+1.16%	+16.60%	+28.83%	14.82B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.54%	-1.03%	+80.71%	+39.94%	14B
Average	+0.06%	-0.15%	+77.38%	+105.79%	30.86B
Weighted average by Cap.	+0.21%	-0.64%	+92.53%	+122.95%

See all sector performances

Yield10 Bioscience, Inc., formerly Metabolix, Inc., is an agricultural bioscience company. The Company is focused on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, the Company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn. The Company concentrates on technologies that enables it to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter. The Company has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	229K 197K 185K 169K 316K 21.66M 318K 2.19M 852K 11.07M 860K 842K 35.65M	P/E 2022	-0.6x	P/E 2023	-0.13x
Enterprise Value	2.34M 2.01M 1.89M 1.73M 3.23M 221M 3.25M 22.34M 8.7M 113M 8.78M 8.59M 364M	EV / Sales 2022	14.6x	EV / Sales 2023	83x
Free-Float	-	Yield 2022 *	-	Yield 2023	-

31/10/25	Yield10 Bioscience, Inc. Went Out of Business	CI
14/10/25	First Amended Joint Liquidation Plan Approved for Yield10 Bioscience, Inc.	CI
20/08/25	First Amended Disclosure Statement Approved for Yield10 Bioscience, Inc.	CI
18/08/25	First Amended Joint Liquidation Plan and Disclosure Statement Filed by Yield10 Bioscience, Inc.	CI
10/07/25	Joint Liquidation Plan and Disclosure Statement Filed by Yield10 Bioscience, Inc.	CI
08/01/25	Motion for Asset Sale Approved for Yield10 Bioscience, Inc.	CI
10/12/24	Motion for Joint Administration Approved for Yield10 Bioscience, Inc.	CI
07/12/24	Yield10 Approves Wind Down of Operations and Corresponding Reduction in Workforce	CI
07/12/24	Yield10 Bioscience, Inc. Announces Board Changes	CI
06/12/24	Motion for Asset Sale Filed by Yield10 Bioscience, Inc.	CI
06/12/24	Yield10 Bioscience, Inc. Filed for Bankruptcy	CI
06/12/24	Motion for Joint Administration Filed by Yield10 Bioscience, Inc.	CI
12/11/24	Yield10 Bioscience, Inc. announced that it has received $3 million in funding	CI

	2022	2023
Net sales	450K 387K 363K 332K 620K 42.54M 625K 4.3M 1.67M 21.74M 1.69M 1.65M 70.01M	60K 51.62K 48.44K 44.32K 82.73K 5.67M 83.38K 573K 223K 2.9M 225K 220K 9.34M
Net income	-13.57M -11.67M -10.95M -10.02M -18.7M -1.28B -18.85M -130M -50.46M -655M -50.94M -49.83M -2.11B	-14.46M -12.44M -11.67M -10.68M -19.93M -1.37B -20.09M -138M -53.77M -698M -54.28M -53.1M -2.25B
Net Debt	-1.7M -1.46M -1.37M -1.25M -2.34M -160M -2.36M -16.21M -6.31M -81.98M -6.37M -6.23M -264M	2.11M 1.82M 1.7M 1.56M 2.91M 199M 2.93M 20.15M 7.85M 102M 7.92M 7.75M 328M

Metabolix, Inc. Stock Nasdaq

Stocks

US5910188094

Biotechnology & Medical Research

Valuation : Metabolix, Inc.

Latest news : Metabolix, Inc.

Analysts' recommendations : Metabolix, Inc.

Press Releases : Metabolix, Inc.

Quotes and Performance

Managers and Directors : Metabolix, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile